USFDA Flags Two Observations at Dr. Reddy's Mexico API Facility
RDY is trading near its 52-week low of $11.36 (4.8% above the low).
Summary
The USFDA issued two observations after a records assessment at Dr. Reddy's Mexico API facility, adding to a string of recent inspection findings across the company's manufacturing network.
Key Events · Product Development and Regulatory · RDY
-
USFDA Issues Two Observations at Mexico API Site
Between July 17 and September 8, 2026, the USFDA conducted a Section 704(a)(4) records assessment at Dr. Reddy's Mexico API facility in Jiutepec, Morelos, and issued a Form FDA 2953 with two observations.
-
Fourth USFDA Inspection Finding in Three Months
This latest action follows Form 483s at the biologics facility on June 26, the Srikakulam plant on July 29, and the Bachupally formulation site on August 17, indicating a pattern of recurring regulatory observations across the manufacturing network.
-
Company to Respond Within Stipulated Timeline
Dr. Reddy's stated it will respond to the two observations within the USFDA's stipulated timeline; no details on the nature or severity of the observations were disclosed.
-
Compounds Existing Semaglutide Quality Issue
The new observations add to existing quality concerns after a semaglutide API impurity halted commercial supplies and triggered a ₹2.4B provision in Q1 FY27.
Analysis · RDY · Life Sciences
The USFDA has completed a records assessment at Dr. Reddy's Mexico API facility and issued a Form FDA 2953 with two observations. This marks the fourth USFDA inspection-related disclosure in roughly three months, following Form 483s at the biologics, Srikakulam, and Bachupally sites. While the observation count is lower than in some prior inspections, the recurring pattern of regulatory findings across multiple facilities is a growing compliance concern for a company already grappling with a semaglutide API quality issue that halted supplies.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDY was trading at $11.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $11.36 to $15.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.